Participant flow

Afatinib in Advanced Refractory Urothelial Cancer · Source last updated 2025-04-25

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   Patients receive afatinib dimaleate PO QD on days 1-42. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. afatinib dimaleate: Given PO laboratory biomarker analysis: Correlative studies

   id

   FG000

   title

   Treatment (Afatinib)

periods

1. milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         32

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         23

      type

      Main Phase II Study

   3. achievements

      1. group Id

         FG000

         num Subjects

         9

      comment

      Based on encouraging results from the main Phase II study, a molecularly selected cohort was enrolled

      type

      Molecularly Selected Cohort

   4. achievements

      1. group Id

         FG000

         num Subjects

         32

      type

      COMPLETED

   5. achievements

      1. group Id

         FG000

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice